EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015
ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.
Stem cell historical CryoSave’s core business now profitable and improving.
Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.
Zutphen, The Netherlands – 17 March 2015